Sunshine Biopharma Inc. (SBFM) stock intrinsic value fair value estimate & owner earnings analysis

Sunshine Biopharma (SBFM) is, in practice, a Canadian generic-drug distributor. Its Montreal-based subsidiary Nora Pharma, acquired in October 2022, sells roughly 70 generic prescription products under its own label in Quebec, Ontario, Alberta and British Columbia, sourcing most of them from overseas manufacturers. It generated $36.3M of revenue in 2025 (up 4% from $34.9M) at a 33.8% gross margin. A small oncology and antiviral drug-development effort is a minor side activity. The problem is that the business does not yet make money. General and administrative costs were $18.5M in 2025 (about $16.7M before a $1.7M write-down of acquired product rights), more than the roughly $12.3M of gross profit. Cash used in operations was $12.5M in 2024 and $5.3M in 2025. We measure earning power as operating cash flow less working-capital swings, stock compensation and the capital spending needed to stay in business. On that basis the company lost roughly $4.4M in 2023, $6.4M in 2024 and $4.0M in 2025. The improvement from 2024 to 2025 (about a 37% narrowing) came mostly from slower inventory build-up rather than from higher profitability. The write-down of acquired rights is a non-cash item, and we did not deduct it a second time. Because the business has yet to earn anything, the write-downs matter here as a caution: some of the product rights bought since 2022 are not paying back. What the first half of 2026 shows: revenue was $17.4M versus $18.3M a year earlier (down about 5%), and operating cash outflow was $3.0M versus $3.0M. That flat headline hides a release of inventory of about $0.9M; excluding working-capital swings the underlying loss was larger than in the first half of 2025. We therefore see no evidence yet that the cost cuts announced in January 2026 (management targets $2M to $3M of savings) are showing up in cash flow. These figures come from the company's quarterly filing data; the underlying quarterly document itself was not available for us to read. What the shares appear to be worth. We credit growth only if it is secured or proven. Nothing here qualifies: the 2025 revenue increase was small, the first half of 2026 declined, the cost savings are a target, and new product launches are not yet earning anything. So the earning-power figure we start from is the 2025 loss, not a profit. Bear case (worth $0 per share): the burn of about $4M to $5M a year continues; cash of $9.1M at year-end 2025 (about $6M by mid-2026 after the first-half burn) runs out around late 2027. The company must then raise equity at a much lower price or restructure. The company has a track record of diluting: the share count has been reduced by five reverse splits, and weighted shares rose from 0.7M to 4.2M between 2024 and 2025 on a split-adjusted basis. Holders end up with essentially nothing. We do not go below $0 because the company carries little debt. Base case (worth $0 per share): the median path is that the business keeps losing $4M or so a year through 2027, spending its cash. Management says existing cash covers 18 months of operations, and that is consistent with our arithmetic, but there are no committed funding sources. On the evidence, the operations produce no owner earnings, so we assign them no value. Nora Pharma's revenue, its roughly 200 drug registrations and its distribution relationships have value to some acquirer, but we cannot name an acquirer, a price or a plan, so it is left out. Bull case (about $0.60 per share): the January 2026 cost reductions are delivered in full, gross margin holds near the 2025 level of 34%, and cash burn shrinks to break-even during 2027. In that case roughly $3M of cash (about $0.60 on the 4.9M shares outstanding in April 2026) would remain for shareholders. We give no value to earnings after break-even, since nothing in the record yet shows the business making a profit. Accounting judgements. We treated the $2.25M earn-out payment to Nora's sellers in 2024 as a one-time working-capital-like item and removed it. We counted only equipment purchases as capital spending; purchases of product rights ($0.7M in 2025, $0.3M in 2024) were treated as discretionary. Because this company burns cash rather than earning it, our usual approach (which does not credit or subtract cash) would ignore the cash pile; here, because the cash is the only thing of demonstrated value, the bull-case value consists of cash left over after operating losses. Per-share figures for 2023 and 2024 look very large because of five reverse stock splits and heavy dilution. What would make this wrong. The value is higher if the January 2026 cost cuts plus Nora's new launches move the company to profit faster than we see in the first-half numbers, or if the business were sold for a meaningful price. It is lower, and the shares could be worth nothing, if the cash runs out before break-even or if Nasdaq listing is lost; the stock has been trading close to the $1.00 minimum bid price, and management has stockholder approval for another reverse split of up to 1-for-10.